Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ZBQGY
ADC Name	TW202444426A ADC-032
Synonyms	TW202444426A ADC-032 Click to Show/Hide
Organization	EXELIXIS, INC.
Drug Status	Investigative
Drug-to-Antibody Ratio	8
Structure
Antibody Name	Anti-mAb304	Antibody Info
Antigen Name	Undisclosed
Payload Name	Undisclosed
Therapeutic Target	Stimulator of interferon genes protein (STING1)	Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal inhibitory Concentration (IC50)Human PBMC	308.55	nM	CVCL_2010	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	308.55 nM	Positive XXX expression (XXX+++/++)
Method Description	The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
In Vitro Model	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary	COV434-AMRH2 cells		CVCL_2010

References

Ref 1	AMHRII antibody-drug conjugates and uses thereof